TrialESMO open2024

Tislelizumab plus chemotherapy as first-line treatment of locally advanced or metastatic nonsquamous non-small-cell lung cancer (final analysis of RATIONALE-304: a randomized phase III trial).

S Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.